UA90467C2 - Применение пептидных соединений для лечения боли при болезненой диабетической невропатии - Google Patents

Применение пептидных соединений для лечения боли при болезненой диабетической невропатии

Info

Publication number
UA90467C2
UA90467C2 UAA200610139A UAA200610139A UA90467C2 UA 90467 C2 UA90467 C2 UA 90467C2 UA A200610139 A UAA200610139 A UA A200610139A UA A200610139 A UAA200610139 A UA A200610139A UA 90467 C2 UA90467 C2 UA 90467C2
Authority
UA
Ukraine
Prior art keywords
treating pain
diabetic neuropathy
peptide compounds
painful diabetic
painful
Prior art date
Application number
UAA200610139A
Other languages
English (en)
Ukrainian (uk)
Inventor
Кристина Раушкольб-Лофлер
Бригитта Кох
Original Assignee
Шварц Фарма Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шварц Фарма Аг filed Critical Шварц Фарма Аг
Publication of UA90467C2 publication Critical patent/UA90467C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Это изобретение касается применения некоторых пептидных соединений для лечения боли при болезненой диабетической невропатии, преимущественно при диабетической периферической сенсорной полиневропатии.
UAA200610139A 2004-03-26 2005-03-24 Применение пептидных соединений для лечения боли при болезненой диабетической невропатии UA90467C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04007360A EP1579858A1 (en) 2004-03-26 2004-03-26 Novel use of peptide compounds for treating pain in painful diabetic neuropathy

Publications (1)

Publication Number Publication Date
UA90467C2 true UA90467C2 (ru) 2010-05-11

Family

ID=34854637

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200610139A UA90467C2 (ru) 2004-03-26 2005-03-24 Применение пептидных соединений для лечения боли при болезненой диабетической невропатии

Country Status (15)

Country Link
US (1) US20060100157A1 (ru)
EP (2) EP1579858A1 (ru)
JP (1) JP2007530493A (ru)
CN (1) CN1938010B (ru)
AU (1) AU2005226928B2 (ru)
BR (1) BRPI0509211A (ru)
CA (1) CA2558311A1 (ru)
EA (1) EA012176B1 (ru)
MX (1) MXPA06010995A (ru)
NZ (1) NZ549668A (ru)
SG (1) SG151309A1 (ru)
TW (1) TW200701977A (ru)
UA (1) UA90467C2 (ru)
WO (1) WO2005092313A1 (ru)
ZA (1) ZA200607269B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE327744T1 (de) 2001-03-20 2006-06-15 Sanol Arznei Schwarz Gmbh Neue verwendung von peptidverbindungen bei der behandlung von nicht-neuropathischem entzündungsschmerz
DE60100055T2 (de) * 2001-03-21 2003-07-24 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
US7794987B2 (en) 2003-12-02 2010-09-14 Ucb Pharma Gmbh Method for treating central neuropathic pain
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
KR20070007931A (ko) 2004-04-16 2007-01-16 쉬바르츠파르마에이지 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
PL1781276T3 (pl) 2004-08-27 2010-11-30 Ucb Pharma Gmbh Zastosowanie związków peptydowych do leczenia bólu związanego z rakiem kości, bólu indukowanego przez chemioterapię oraz nukleozydy
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US7902401B2 (en) * 2006-12-14 2011-03-08 Nps Pharmaceuticals, Inc. Fluorinated compounds
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
CA2652667A1 (en) * 2006-06-08 2007-12-13 Schwarz Pharma Ag Therapeutic combination for painful medical conditions
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
EA019757B1 (ru) 2006-06-15 2014-06-30 ЮСиБи ФАРМА ГМБХ Фармацевтическая композиция с синергетическим противосудорожным эффектом
US8450336B2 (en) * 2006-12-14 2013-05-28 Nps Pharmaceuticals, Inc Use of D-serine derivatives for the treatment of anxiety disorders
US8829033B2 (en) 2009-09-23 2014-09-09 The University Of North Carolina At Chapel Hill N-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
ES2753141T3 (es) * 2009-11-03 2020-04-07 Lupin Ltd Formulación de liberación modificada de lacosamida
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
EP2646001A2 (en) 2010-12-02 2013-10-09 UCB Pharma GmbH Formulation of lacosamide
EP3397253A1 (en) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5585358A (en) * 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
US6589994B1 (en) * 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
DK1311256T3 (da) * 2000-08-17 2005-11-28 Teva Pharma Anvendelse af derivater af valproinsyreamider og 2-valproinsyreamider til behandling eller forebyggelse af smerter og/eller hovedpinelidelser
CA2419285C (en) * 2000-08-25 2011-08-02 Research Corporation Technologies, Inc. New uses for amino acid anticonvulsants
ATE327744T1 (de) * 2001-03-20 2006-06-15 Sanol Arznei Schwarz Gmbh Neue verwendung von peptidverbindungen bei der behandlung von nicht-neuropathischem entzündungsschmerz
DE60100055T2 (de) * 2001-03-21 2003-07-24 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
US7794987B2 (en) * 2003-12-02 2010-09-14 Ucb Pharma Gmbh Method for treating central neuropathic pain
US20060009384A1 (en) * 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
KR20070007931A (ko) * 2004-04-16 2007-01-16 쉬바르츠파르마에이지 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EP1604654A1 (en) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604656A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain

Also Published As

Publication number Publication date
MXPA06010995A (es) 2007-04-16
CN1938010A (zh) 2007-03-28
NZ549668A (en) 2010-07-30
JP2007530493A (ja) 2007-11-01
EP1737437A1 (en) 2007-01-03
ZA200607269B (en) 2008-04-30
EA012176B1 (ru) 2009-08-28
AU2005226928A1 (en) 2005-10-06
AU2005226928B2 (en) 2010-05-13
US20060100157A1 (en) 2006-05-11
WO2005092313A1 (en) 2005-10-06
CA2558311A1 (en) 2005-10-06
EP1579858A1 (en) 2005-09-28
CN1938010B (zh) 2011-01-19
TW200701977A (en) 2007-01-16
BRPI0509211A (pt) 2007-08-28
EA200601777A1 (ru) 2007-02-27
SG151309A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
SG151309A1 (en) Novel use of peptide compounds for treating pain in painful diabetic neuropathy
TW200637522A (en) Skin treatment articles and methods
PL381247A1 (pl) Skondensowana pochodna heterocykliczna, zawierająca ją kompozycja lecznicza, oraz jej zastosowanie lecznicze
FR2869231B1 (fr) Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
SG155912A1 (en) B-cell reduction using cd37-specific and cd20-specific binding molecules
UA98629C2 (ru) Соединения и способ модуляции киназ
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
AU3831301A (en) Method for treating ocular pain
ATE468332T1 (de) Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin- - yi)aminderivate
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
MXPA05011233A (es) Vectores peptidicos.
PL1919466T3 (pl) Formulacje do leczenia nieprawidłowości lipoproteinowych obejmujące statynę i pochodną metylonikotynoamidu
UA85471C2 (ru) Применение оксикодона для лечения висцеральной боли
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
EA201070193A1 (ru) Лечение детских опухолей
UA87117C2 (ru) Применение пептидных соединений для лечения центральной невропатической боли
ZA200703992B (en) 5, 6, 7-Trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses
PL1612210T3 (pl) Nowe analogi nitrobenzylotioinozyny
PL1843771T3 (pl) Zastosowanie pirymidyloaminobenzamidów do leczenia chorób odpowiadających na modulację aktywności kinazy Tie-2
EA200800537A1 (ru) Маррубиин и композиция для уменьшения храпа, упаковка и методика
AU2003227593A1 (en) New analogs of nitrobenzylthioinosine
TW200628168A (en) Use of organic compounds
FR2885128B1 (fr) Composition cosmetique a visee depigmentante ou eclaircissante comprenant au moins une oxazoline, a titre de principe actif depigmentant ou eclaircissant
NO20064828L (no) Ny anvendelse av peptidforbindelser for behandling av smerte i smertefull diabetisk neuropati.